A number of studies [21, 28–30] showed that the mutation rates of EGFR and ALK genes in patients with PPLELC were significantly lower than those in non-small-cell lung cancer patients, and the benefit of targeted therapy was small, but 63.3%-75.8% of patients with PPLELC expressed PD-L1. Here, ALK is linked to non-small cell lung carcinoma.